Home' Australian Pharmacist : Australian Pharmacist March 2012 Contents Australian Pharmacist March 2012 I ©Pharmaceutical Society of Australia Ltd. 213
Continuing Professional Development
Submit your answers online at www.psa.org.au and receive automatic feedback
provision of health services. Mathematical
modelling, using different prevalence and
sequelae of chlamydia such as infertility
and ectopic pregnancies, could assist with
assessing costs and benefits. More work
is needed on the economics of offering
screening in community pharmacies
including a comparison of the costs of
screening programs in other settings.
The potential harm of screening for
disease also needs to be considered.
Screening for, and diagnosis of,
chlamydial infection can be associated
with social stigma, including negative
stereotyping, tensions and suspicion
Screening programs should be
delivered in conjunction with other
health promotion strategies to raise
awareness about the risks associated with
undetected chlamydial infection and the
importance of safe sex practices.
This article focuses on screening for
chlamydia. However, pharmacies
can provide screening for a range of
diseases to groups that otherwise
may not access services. An effective
pharmacy screening program requires
the provision of a clear public health
message, community engagement,
appropriate advertising, staff training
and remuneration for pharmacies.
Screening and risk assessment is
an opportunity for pharmacists
and pharmacy assistants to make a
significant contribution to public health.
Marian J Currie (Research Program
Manager Academic Unit of Internal
Medicine, The Australian National
University Medical School) for providing
background information about
Sarah J Martin (Staff Specialist, Canberra
Sexual Health Centre, Canberra Hospital)
for assisting with the case study.
1. Australian Health Ministers' Advisory Council. Population Based
Screening Framework. Canberra: Commonwealth of Australia;
2. Pharmaceutical Society of Australia. Professional Practice
Standards, version 4. Canberra: PSA; Jun 2010.
3. Wilson JMG, Jungner G. Geneva: World Health Organisation,1968.
4. Krass I, Mitchell B, Clarke P, et al. Pharmacy diabetes care
program: analysis of two screening methods for undiagnosed
type 2 diabetes in Australian community pharmacy. Diabetes
Res Clin Pract. 2007; 75(3):339--47.
5. Allan H, Diamandis S, Saini B, et al. A collaborative screening,
referral and management process to improve health outcomes
in chronic obstructive pulmonary disease (COPD). Pharmacy
Guild of Australia Research and Development Program; 2010.
6. Naunton M, Peterson GM, Jones G. Pharmacist-provided
quantitative heel ultrasound screening for rural women at risk of
osteoporosis. Ann Pharmacother. 2006; 40(1):38--44.
7. Peterson GM, Fitzmaurice KD, Kruup H, et al. Cardiovascular risk
screening program in Australian community pharmacies. Pharm
World Sci. 2010;32(3):373--80.
8. Hourihan F, Krass I, Chen T. Rural community pharmacy: a
feasible site for a health promotion and screening service for
cardiovascular risk factors. Aust J Rural Health. 2003; 11(1):28--35.
9. Howard K, Salkeld G. Home bowel cancer tests and informed
choice -- is current information sufficient? Aust NZ J Public
Health. 2003; 27:513--6.
10. Emmerton L, Buhrer Skinner M, Gardiner E, et al. A trial of the
distribution of chlamydia self-collection postal specimen kits
from Australian community pharmacies. Sex Health. 2010;
11. Gudka S, Marshall L, Creagh A, et al. To develop and pilot a best
practice community pharmacy chlamydia screening model.
Pharmacy Guild of Australia Research and Development
1. What percentage of women infected
with genital chlamydia are not aware
of any symptoms?
a) Less than 25%.
b) Between 25 and 49%.
c) Between 50 and 74%.
d) More than 75%.
2. What is the standard first line
treatment for a positive chlamydia
a) Metronidazole 400 mg three times a
day for one week.
b) Doxycycline 100 mg twice a day for
c) Azithromycin 1 g as a single dose.
d) Azithromycin 2 g as a single dose.
3. Following a positive chlamydia test,
how far back should sexual partners
(contacts) be traced?
a) Nine months.
b) One month.
c) Three months.
d) Six months.
4. What is your advice to a man who
comes into the pharmacy and tells
you that he had unprotected sex with
a man last month so he wants a urine
a) Homosexual men cannot get
b) He is unlikely to want to have children
so there is no need to be tested.
c) Could he wait while you call the local
sexual health centre for advice?
d) Chlamydia does not infect the rectum.
A score of 3 out of 4 attracts 1 CPD credit.
12. Teh R, Chen T, Krass I. Consumer perspectives of pharmacist-
delivered health information and screening services. Int J Pharm
Pract. 2001; 9(4):261--7.
13. Australian Government Department of Health and Ageing.
National Notifiable Disease Surveillance System [online]. 2012.
14. Sexual Health Society of Victoria. National Management
Guidelines for Sexually Transmissible Infections [online]. 2008.
15. Centers for Disease Control and Prevention. CDC Fact Sheet.
The Role of STD Prevention and Treatment in HIV Prevention.
16. Darville T. Chlamydia trachomatis Infections in Neonates and
Young Children. Semin Pediatr Infect Dis. 2005; 16:235--44.
17. Stamm W. Biology of Chlamydia trachomatis. In: Holmes KK,
Stamm WE, Wassenheit JM, et al., eds. Sexually Transmitted
Infections. 4th edn. McGraw-Hill; 2007.
18. Chlamydial or other nongonococcal infection [revised 2010 Jun].
In: eTG complete [online]. Melbourne: Therapeutic Guidelines;
2011 [accessed 4 Jan 2012]. At: http://online.tg.org.au/ip
19. Lau CY, Qureshi AK. Azithromycin versus doxycycline for genital
chlamydial infections: A meta-analysis of randomized clinical
trials. Sex Transm Dis. 2002; 29:497--502.
20. Kong FY, Guy RJ, Hocking JS, et al. Australian general practitioner
chlamydia testing rates among young people. MJA. 2010;
21. Balfe M, Brugha R, O' Connell E, et al. Where do young Irish
women want Chlamydia-screening services to be set
up? A qualitative study employing Goffman's impression
management framework. Health & Place. [doi: 10.1016/j.
healthplace.2009.07.003]. 2010; 16(1):16--24.
22. Baraitser P, Pearce V, Holmes J, et al. Chlamydia testing in
community pharmacies: evaluation of a feasibility pilot in south
east London. Qual Saf Health Care. 2007; 16(4):303--7.
23. TNS Healthcare. Pharmacy Chlamydia Screening Pathfinder
Evaluation (PCSPf ) Final: Wave Three. London Department of
24. Brabin L, Thomas G, Hopkins M, et al. Delivery of chlamydia
screening to young women requesting emergency hormonal
contraception at pharmacies in Manchester, UK: a prospective
study. BMC Women's Health. 2009; 9:7.
25. Marrazzo JM, Whittington WL, Celum CL, et al. Urine-based
screening for Chlamydia trachomatis in men attending sexually
transmitted disease clinics. Sex Transm Dis. 2001; 28(4):219--25.
26. Schachter J, McCormack WM, Chernesky MA, et al. Vaginal
swabs are appropriate specimens for diagnosis of genital tract
infection with Chlamydia trachomatis. J Clin Microbiol. 2003;
27. Pimenta JM, Catchpole M, Rogers PA, et al. Opportunistic
screening for genital chlamydial infection. I: acceptability of
urine testing in primary and secondary healthcare settings. Sex
Transm Infect. 2003; 79(1):16--21.
28. Australian Government Department of Health and Ageing.
Medicare Benefits Schedule Book Category 6 Operating from 01
Jan 2012. Canberra; 2012.
29. Pimenta JM, Catchpole M, Rogers PA, et al. Opportunistic
screening for genital chlamydial infection. II: prevalence among
healthcare attenders, outcome, and evaluation of positive cases.
Sex Transm Infect. 2003; 79(1):22--7.
Links Archive Australian Pharmacist April 2012 Australian Pharmacist February 2012 Navigation Previous Page Next Page